8-K: BioSig Technologies Secures $818,997.91 Through Securities Purchase Agreement

BioSig Technologies entered into a Securities Purchase Agreement to sell shares and warrants for an aggregate consideration of $818,997.91.

Summary

• BioSig Technologies, Inc. entered into a Securities Purchase Agreement on March 5, 2025, with accredited investors.
• The company sold 758,514 shares of common stock at $1.07974 per share.
• Warrants to purchase up to 758,514 shares of common stock were also issued with an exercise price of $0.95474 per share.
• The warrants become exercisable six months after issuance and expire three and a half years after the issuance date.
• The aggregate consideration received was $818,997.91.
• From January 17, 2025 through March 5, 2025, the Company has sold 4,413,807 ATM Shares at an average offering price of $0.912704 per share for aggregate gross proceeds of $4,028,498.73.
• The company intends to use the net proceeds for research and development of the company's PURE EP platform and working capital purposes.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company has secured funding, it comes with the cost of dilution. The success of the company hinges on the effective use of these funds for R&D and working capital.

Positives

• The company successfully raised $818,997.91 through the sale of shares and warrants.
• The funds are intended to be used for research and development of the PURE EP platform and for working capital, which could drive future growth.
• The warrants have a defined exercise period, potentially providing additional capital to the company in the future.

Negatives

• The issuance of new shares will dilute existing shareholders' equity.
• The exercise of warrants could further dilute existing shareholders' equity.
• The company is reliant on future stock sales to fund operations.

Risks

• The company's reliance on future stock sales to fund operations.
• The market price of the company's stock could be negatively impacted by the issuance of new shares.
• The company's ability to successfully develop and commercialize the PURE EP platform is subject to various risks and uncertainties.

Future Outlook

The company intends to use the net proceeds from the sale of the Securities hereunder for research and development of the Company's PURE EP platform and working capital purposes.

Industry Context

The announcement reflects a common financing strategy for companies in the technology and medical device sectors, which often require significant capital for research, development, and commercialization.

Comparison to Industry Standards

• Comparable companies in the medical device industry, such as Medtronic or Boston Scientific, typically have diverse funding sources, including revenue from existing products, debt financing, and strategic partnerships.
• Smaller companies often rely more heavily on equity financing, similar to BioSig's approach.
• The terms of the warrants, such as the exercise price and expiration date, are generally consistent with industry standards for similar financing transactions.

Stakeholder Impact

• Existing shareholders will experience dilution due to the issuance of new shares.
• The company's employees and customers may benefit from the research and development of the PURE EP platform.
• The company's creditors may be impacted by the company's increased debt levels.

Next Steps

• The company will file a Current Report on Form 8-K with the Commission.
• The company will apply to list the Shares and Warrant Shares on the Trading Market.
• The company will use the net proceeds for research and development of the PURE EP platform and working capital purposes.

Key Dates